Zenas BioPharma (ZBIO) is in focus after reporting Phase 2 data showing its multiple sclerosis candidate obexelimab achieved a 95% reduction in brain lesions and announcing two concurrent public offerings raising US$300 million.

The latest clinical and fundraising updates arrive after a volatile stretch, with the 1-year total shareholder return of 62.42% contrasting with a year-to-date share price return of negative 43.88%, while recent 7-day gains suggest short term momentum picking up again.

If this kind of biotech catalyst has your attention, it could be a useful moment to scan for other healthcare AI opportunities using the 33 healthcare AI stocks.

With Zenas trading at US$19.36 against an analyst price target of US$42 and backed by fresh clinical data and US$300 million in new funding, is the stock still mispriced, or is the market already accounting for potential future growth?

Preferred Price-to-Book of 4.8x: Is it justified?

At a last close of $19.36 and a P/B of 4.8x, Zenas BioPharma trades at a richer valuation than the broader US biotechs industry, which sits at 2.3x.

The P/B ratio compares the stock price to the accounting value of net assets. This measure is often watched closely for early stage drug developers where earnings are still negative. For a clinical stage company like Zenas, this metric essentially reflects what investors are willing to pay today for its pipeline, intellectual property and future revenue potential, relative to its current balance sheet.

What stands out is the split between industry and peer comparisons. Against the wider US biotechs group, Zenas looks expensive at 4.8x versus 2.3x. This suggests the market is assigning a richer premium than the typical biotech stock. Yet when lined up against a closer peer set, its 4.8x P/B is below the 15.2x peer average, indicating there are other companies investors are paying a much higher multiple for, even with similar sector risks and early stage profiles.

Result: Price-to-book of 4.8x (ABOUT RIGHT)

However, investors still face clear risks, including clinical setbacks for obexelimab or other pipeline assets, as well as the company’s US$377.737 million net loss on modest US$10 million revenue.

Next Steps

With sentiment clearly mixed, it could be worth checking the data yourself and deciding where you stand before the next catalyst hits, starting with the 2 key rewards and 2 important warning signs.

Looking for more investment ideas?

If you stop with just one stock, you could miss other opportunities that better suit your goals, risk comfort and income needs, so broaden your watchlist now.

• Target potential mispricing by checking stocks that look attractively valued on both quality and fundamentals using the 51 high quality undervalued stocks.
• Strengthen your defense by reviewing companies with robust finances and healthy balance sheets through the solid balance sheet and fundamentals stocks screener (44 results).
• Spot early-stage opportunities with strong underlying metrics before they gain wider attention via the screener containing 25 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.